ACO Participation Waiver Disclosure:

The Secretary of U.S. Department of Health and Human Services has provided waivers of certain federal laws that may otherwise limit innovation by ACOs. In accordance with the public disclosure requirements of the ACO Participation Waivers set forth in 80 Fed. Reg. 66725 (Oct. 29, 2015), the applicable arrangements are described below:

Agreements with LabCorp: The parties to the arrangement include Prime Accountable Care, LLC (“Prime”) and Laboratory Corporation of America Holdings and its subsidiaries(“LabCorp”). The agreements are effective as of July 2, 2018. Under the agreements, the parties will coordinate with each other to meet requirements for reporting quality and cost measures, establish clinical decision support programs to support chronic disease management and population health strategies, and evaluate and address the health needs of Prime’s patient population. LabCorp will make available laboratory testing services to Prime’s providers, and Prime will integrate and use this information in Prime’s data analytics programs, reporting measures, and care coordination and intervention strategies. The agreements include a series of potential grants to develop infrastructure and redesigning care processes to allow for high quality and efficient service delivery for patients whereby Prime must meet certain quality metrics to be eligible. This arrangement allows the parties to promote accountability for the quality, cost and overall care for Prime’s patients and manage and coordinate care for these individuals.

With respect to this arrangement above, Prime’s governing body has made and duly authorized a bona fide determination that the arrangement is reasonably related to the purposes of the Medicare Shared Savings Program.